Published On: Tue, Apr 22nd, 2014

Israeli Brainsway rises on clinical trial success for Parkinson’s disease

BRAINSWAY


Brainsway Ltd. (TASE:BRIN) today reported success in a clinical trial on Parkinson’s disease. The company reported the final results of a double-blind clinical trial to test the effect of its Deep TMS (transcranial magnetic stimulation) device for the treatment of Parkinson’s disease. The trial was conducted at the San Raffaelle Medical center in Milan.

 Brainsway’s share price rose 4.8% in morning trading, following the announcement, to NIS 57.05, giving a market cap of NIS 810 million (about $230 million) .

The study included 60 patients with Parkinson’s disease. Brainway says that all the patients completed the treatment period and that no significant side effects were reported.

The patients were divided into three groups: those who received real treatment of the motor cortex and prefrontal cortex; those who received real treatment of the motor cortex and placebo treatment of the prefrontal cortex; and those who received placebo treatment of the motor cortex and prefrontal cortex. The assignment of the patients, who received three weekly treatments over four weeks, was random and double-blind (neither the patient nor the researcher knew which group a patient belonged to).

The researchers said that the treatment was found to be safe and resulted in significant clinical improvement among the Parkinson’s patients, and that the results support a subsequent multicenter clinical trial.

Published by Globes [online], Israel business news – www.globes-online.com 

Read more about: , ,

Wordpress site Developed by Fixing WordPress Problems